Novavax Inc (NASDAQ:NVAX)
| 7.25 Delayed Data As of Sep 29 |  +0.09 / +1.26%Today’s Change | 5.61 Today|||52-Week Range 25.66 | -29.47% Year-to-Date |
Latest NVAX News | Press Releases
| Why Pfizer and BioNTech Stocks Zoomed Higher Today Sep 29 / MotleyFool.com - Paid Partner Content | You Can Pick Up These High-Risk, High-Reward Stocks for Less Than $10 Sep 19 / MotleyFool.com - Paid Partner Content |
| Does This Message From Moderna Mean Bad News for Novavax? Sep 21 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 7.16 |
| Today’s open | 7.32 |
| Day’s range | 7.16 - 7.68 |
| Volume | 397,634 |
| Average volume (3 months) | 8,161,242 |
| Market cap | $685.4M |
Data as of 4:00pm ET, 09/29/2023
Growth & Valuation
| Earnings growth (last year) | +64.09% |
| Earnings growth (this year) | +74.87% |
| Earnings growth (next 5 years) | -69.66% |
| Revenue growth (last year) | +72.89% |
| P/E ratio | NM |
| Price/Sales | 0.41 |
| Price/Book | -- |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| TVTXTravere Therapeutics... | -0.03 | -0.33% |
| SAVACassava Sciences Inc | -0.22 | -1.30% |
| RGNXRegenxbio Inc | -1.21 | -6.84% |
| EDITEditas Medicine Inc | +0.87 | +12.57% |
Data as of 4:00pm ET, 09/29/2023
Financials
| Next reporting date | November 2, 2023 |
| EPS forecast (this quarter) | -$0.39 |
| Annual revenue (last year) | $2.0B |
| Annual profit (last year) | -$657.9M |
| Net profit margin | -33.20% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
